Two McKinsey & Company executives share their views on pharma’s digital trajectory, including the role of manufacturing ‘lighthouses’ and opportunities to deploy digital and analytical tools across the entire value chain for both innovator and generic firms. They see Amazon’s playbook on leveraging digital technology as holding some interesting lessons for pharma.
Pharma appears increasingly keen to embrace data science and digital technologies to drive operational and cost efficiencies across the enterprise.
There’s momentum in industry’s efforts to create manufacturing "lighthouses" - facilities that have successfully applied Fourth Industrial Revolution technologies to...
Public Company Edition: Sarepta restructured after stopping shipments of its Elevidys for some patients to ease future debt pressures, but now it has stopped shipments to all patients. Also, Madrigal secured up to $500m in new debt, Cogent closed a $230m offering and other financings.
Looking to improve on the efficacy and safety of Roche’s Esbriet and BI’s Ofev, Avalyn has inhalable formulations of those drugs in Phase IIb and Phase I, respectively.
The drugmaker plans to build a large manufacturing center in Virginia as the centerpiece of an effort to invest $50bn in the US by 2030.
